NASDAQ:IPXL

Impax Laboratories (IPXL) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$17.40
$18.95
50-Day Range
$18.30
$18.30
52-Week Range
$13.05
$25.70
Volume
3.04 million shs
Average Volume
945,265 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IPXL stock logo

About Impax Laboratories Stock (NASDAQ:IPXL)

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

IPXL Stock News Headlines

KBLB Kraig Biocraft Laboratories, Inc.
“Retirement Secret” Showed 995% Gain Last Time We Shared It
Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.
Ferozsons Laboratories Ltd.
Impax Stock Hits New 52-Week High (IPXL)
Morepen Laboratories Ltd (MORL)
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
Abbott Laboratories (NYSE: ABT)
Clearside Biomedical Inc. News
See More Headlines
Receive IPXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impax Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2017
Today
4/26/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:IPXL
CUSIP
45256B10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Chintu Patel
    Co-Chief Executive Officer & Director
  • Chirag K. Patel
    President & Co-Chief Executive Officer & Director
  • Andrew S. Boyer
    Executive Vice President-Commercial Operations
  • Anastasios G. Konidaris
    Chief Financial Officer & Senior Vice President
  • Nikita Shah
    Chief Human Resources Officer & Senior VP

IPXL Stock Analysis - Frequently Asked Questions

How were Impax Laboratories' earnings last quarter?

Impax Laboratories, Inc. (NASDAQ:IPXL) issued its earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.03. The specialty pharmaceutical company earned $206.40 million during the quarter, compared to analyst estimates of $208.38 million. Impax Laboratories's revenue for the quarter was down 9.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.37 EPS.

What other stocks do shareholders of Impax Laboratories own?
This page (NASDAQ:IPXL) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners